Study Title
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma (NCT02275598)
Trial Description
The purpose of this study is to assess the efficacy of two three-weekly 1.8 mg/kg brentuximab vedotin administrations in untreated patients with Hodgkin Lymphoma (HL).
In this trial, treatment with the antibody-drug conjugate brentuximab vedotin is followed with the standard ABVD regimen, a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine) which was developed in the early 1970’s as an alternative to MOPP (mechlorethamine, vincristine, procarbazine and prednisone). The MOPP regimen was first combination regimen for the treatment of Hodgkin’s disease developed in 1964 by researchers at the National Cancer Institute.
This trial is sponsored by University of Modena and Reggio Emilia/ Millennium Pharmaceuticals. [1]
Study Data
- Condition: Hodgkin Lymphoma
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Doxorubicin (Adriamycin®; Pfizer/Doxil®; TTY Bio pharmacy Company Limited)
- Bleomycin (Generic; Teva Parenteral Medicines, Inc.)
- Vinblastine (Generic; APP Pharmaceuticals, LLC)
- Dacarbazine (DTIC-Dome®; Bayer Pharmaceuticals Corporation)
- Drugs used in this trial
- Phase: II
- Enrollment: 12
- Start: April 2013
- Estimated Completion: March 2015
- Last verified: October 2014
Study Schematic
(Coming soon)
Click here to Return to Drug map
Last Editorial review: July 18, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
